Catalyst Pharmaceuticals director equity cancelled in merger
CATALYST PHARMACEUTICALS director Molly Harper reported the disposition to the issuer of 3,694 common shares at $31.50 per share on July 15, 2026, in connection with the acquisition of the company by Angelini Pharma S.p.A.
Rhea-AI Filing Summary
CATALYST PHARMACEUTICALS director Molly Harper reported the disposition to the issuer of 3,694 common shares at $31.50 per share on July 15, 2026, in connection with the acquisition of the company by Angelini Pharma S.p.A. In the same merger-related event, she also disposed of multiple restricted stock units and stock options, which were cancelled and converted into cash rights calculated using the $31.50 merger price, leaving the reported positions at zero.
Positive
- None.
Negative
- None.
Insider Trade Summary
Disposition: 130,857 shares
Disposition
10 txns
Insider
Harper Molly
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to purchase common stock F3, F5 | 12,500 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 20,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 15,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 29,524 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 23,248 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 18,115 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 1,414 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 1,894 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 5,468 | $0.00 | $0.00 |
| Disposition | Common Stock, par value $0.001 per share F1 | 3,694 | $31.50 | $116K |
Holdings After Transaction:
Options to purchase common stock — 0 contracts (Direct);
Restricted Stock Units — 0 contracts (Direct);
Common Stock, par value $0.001 per share — 0 shares (Direct)
Footnotes (6)
- F1. The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
- F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F4. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F5. Each Option was fully vested.
- F6. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Key Figures
Common shares disposed: 3,694 shares
Merger per-share value: $31.50 per share
RSUs cancelled (largest grant): 5,468 units
+3 more
6 metrics
Common shares disposed
3,694 shares
Disposition to issuer at $31.50 per share in connection with the Merger
Merger per-share value
$31.50 per share
Cash value used to calculate consideration for common stock, options and RSUs
RSUs cancelled (largest grant)
5,468 units
Restricted stock units converted into a cash payment based on $31.50 per underlying share
Stock options cancelled (14.15 strike)
29,524 options
Options with $14.15 exercise price cancelled for cash equal to ($31.50 − $14.15) per share
Stock options cancelled (21.12 strike)
23,248 options
Options with $21.12 exercise price cancelled for cash equal to ($31.50 − $21.12) per share
Stock options cancelled (7.07 strike)
20,000 options
Options with $7.07 exercise price cancelled for cash equal to ($31.50 − $7.07) per share
Key Terms
restricted stock unit, stock option, Disposition to issuer, consummation of the acquisition, +1 more
5 terms
restricted stock unit financial
"Each restricted stock unit represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
stock option financial
"each reported stock option ("Option") was cancelled and converted into the right"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Disposition to issuer financial
"transaction_code_description: Disposition to issuer"
consummation of the acquisition financial
"disposed of in connection with the consummation of the acquisition of the Issuer"
Merger financial
"acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Molly Harper report in her Form 4 for CPRX?
Molly Harper reported merger-related dispositions of Catalyst Pharmaceuticals equity on July 15, 2026. She disposed of common shares, restricted stock units, and stock options, all cancelled and converted into cash rights tied to a $31.50 per-share merger price with Angelini Pharma.
What happened to Molly Harper’s RSUs in Catalyst Pharmaceuticals (CPRX)?
Her reported RSUs covering 5,468, 1,894 and 1,414 shares were cancelled in the Merger. Each restricted stock unit represented a right to receive one share, and each was converted into a cash payment based on the $31.50 per-share merger price, less applicable withholdings.
How were Molly Harper’s stock options in CPRX treated in the Angelini Pharma acquisition?
Her reported stock options, including 18,115 options at $22.77 and 23,248 options at $21.12 per share, were cancelled. Each option was converted into a cash right equal to ($31.50 minus the option’s exercise price) multiplied by the number of underlying shares.
Did Molly Harper retain any of the reported Catalyst Pharmaceuticals equity after the Merger?
For every reported security type—common shares, RSUs, and stock options—the Form 4 shows 0 shares following the transaction. This indicates she no longer held these specific reported positions after the merger-related cash conversion and cancellations.
Were Molly Harper’s CPRX RSUs and options vested at the time of the Merger?
Footnotes state that each reported RSU and option vested in full in connection with the consummation of the Merger. The options are also described as fully vested, supporting their cancellation and cash-settlement treatment using the $31.50 per-share merger value.
AI-generated analysis. How Rhea-AI works. Not financial advice.
